Page 101 - Drug Class Review

Drug Effectiveness Review Project
Groups similar at baseline: No (more females in high dose RIV group)
Alzheimer classification: Mild-moderate

Health Outcome Measures: 0.01)

placebo rivastigmine (high) rivastigmine (low) 73.8 74.9 74.8 68 57 58 97% 95% 94% 3% 4% 4% 0% 0% 1% 0% 1% < 1% 38.4 39.3 40.4 19.62 19.5 20 Primary Outcome Measures: ADAS-Cog; CIBIC-plus; PDS Secondary Outcome Measures: MMSE; GDS Timing of assessments: Baseline and weeks 12, 18, 26 or early termination PDS: high-dose RIV vs. placebo difference was significant (P < 0.05); only the high dose RIV group had a significantly greater number of treatment responders than placebo on the PDS (P < Intermediat

• • • •

Final Report Update 1 Authors: Corey-Bloom et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Asian • Other • Other germane population qualities: Mean dementia duration • (months) Mean MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs